Company Information

  

Address: 7 STRAITS VIEW
#12-00, MARINA ONE EAST TOWER 
City: SINGAPORE 
State:  
Zip Code: 018936 
Telephone: 617-949-2900 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biotechnology company with an innovative and proprietary synthetic chemistry drug development platform that we are using to rationally design, develop and commercialize a broad pipeline of first-in-class or best-in-class nucleic acid therapeutic candidates for genetically defined diseases. Nucleic acid therapeutics are a growing and innovative class of drugs that have the potential to address diseases that have historically been difficult to treat with small molecule drugs or biologics. Nucleic acid therapeutics, or oligonucleotides, are comprised of a sequence of nucleotides that are linked together by a backbone of chemical bonds. We are initially developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics we are developing are stereopure.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-4.21NAN/E
12/2017-3.85NAN/E
09/2017-3.54NAN/E
03/2017-2.96NAN/E
12/2016-2.43NAN/E
03/2016-0.37NAN/E
12/2015-1.83NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.31Total Liab/Total Assets0.19
Net Inc/Total Assets-0.56Total Liab/Inv Cap0.21
Net Inc/Inv Cap-0.63Total Liab/Comm Equity0.10
Pretax Inc/Net Sales-27.36Interest Coverage RatioNA
Net Inc/Net Sales-27.55Curr Debt/Equity0.00
Cash Flow/Net Sales-22.59LTD/Equity0.02
SG&A/NetSales7.28Total Debt/Equity0.02
Asset Utilization   Liquidity  
Net Receivables Turnover34.62Quick Ratio7.67
Inventory TurnoverNACurrent Ratio7.67
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.03Inv/Curr AssetsNA
Net Sales/PP&E0.14  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 1.42 1.68 0.68 0.97
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 8.00 6.89 7.57 6.67
Operating Income -35.78 -30.58 -26.99 -24.80
Interest Exp NA NA NA NA
Pretax Income -35.07 -30.41 -26.55 -24.38
Other Income 0.70 0.17 0.44 0.42
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -35.24 -30.21 -26.14 -24.59

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 110.49 142.50 168.46 197.39
Receivables - Total NA 0.00 0.00 0.00
Inventories - Total NA NA NA NA
Total Current Assets 117.96 150.49 173.83 201.22
Net Property, Plant & Equipment 28.78 27.33 24.58 20.78
Total Assets 150.42 181.84 202.09 226.43
Liabilities        
Accounts Payable 14.48 16.50 11.66 12.57
Debt in Current Liabilities 0.48 0.36 0.71 0.28
Total Current Liabilities 16.30 19.62 15.12 15.56
Long-Term Debt 4.19 3.09 2.09 2.20
Total Liabilities 32.50 34.16 28.36 29.65
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 311.59 310.04 309.43 309.36
Retained Earnings -228.31 -192.51 -162.30 -136.17
Treasury Stock NA NA NA NA
Total Stockholders' Equity 110.05 139.81 165.86 188.91
Total Liabilities and Stockholders' Equity 142.55 173.97 194.21 218.56

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -32.43 -22.75 -23.41 -20.09
Net Cash Provided by Investing Activities -1.16 -4.08 -5.61 -5.57
Net Cash Provided by Financing Activities 1.54 0.59 0.06 93.54

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-3.32--
12/20140.00-5.23--
12/20150.15-19.20-1.83
12/20161.48-55.40-2.43
12/20173.70-102.04-3.85
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/188923,67081.33




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.